LEMAITRE VASCULAR INC (LMAT)
US5255582018 - Common Stock
Overall LMAT gets a fundamental rating of 7 out of 10. We evaluated LMAT against 193 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making LMAT a very profitable company, without any liquidiy or solvency issues. LMAT has a correct valuation and a medium growth rate. This makes LMAT very considerable for quality investing!
1. Profitability
1.1 Basic Checks
LMAT had positive earnings in the past year.
LMAT had a positive operating cash flow in the past year.
Each year in the past 5 years LMAT has been profitable.
In the past 5 years LMAT always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 8.68%, LMAT belongs to the best of the industry, outperforming 91.15% of the companies in the same industry.
With an excellent Return On Equity value of 10.11%, LMAT belongs to the best of the industry, outperforming 86.46% of the companies in the same industry.
LMAT has a Return On Invested Capital of 8.87%. This is amongst the best in the industry. LMAT outperforms 88.02% of its industry peers.
The Average Return On Invested Capital over the past 3 years for LMAT is in line with the industry average of 8.53%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.68% | ||
| ROE | 10.11% | ||
| ROIC | 8.87% |
ROA(3y)8.17%
ROA(5y)8.48%
ROE(3y)9.46%
ROE(5y)10.55%
ROIC(3y)8.98%
ROIC(5y)9.18%
1.3 Margins
The Profit Margin of LMAT (15.56%) is better than 92.71% of its industry peers.
In the last couple of years the Profit Margin of LMAT has declined.
LMAT has a better Operating Margin (19.22%) than 92.71% of its industry peers.
In the last couple of years the Operating Margin of LMAT has remained more or less at the same level.
LMAT has a Gross Margin of 65.66%. This is in the better half of the industry: LMAT outperforms 69.27% of its industry peers.
LMAT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.22% | ||
| PM (TTM) | 15.56% | ||
| GM | 65.66% |
OM growth 3Y-4.21%
OM growth 5Y-0.39%
PM growth 3Y-1.71%
PM growth 5Y-6.42%
GM growth 3Y0.15%
GM growth 5Y-1.27%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), LMAT is destroying value.
LMAT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LMAT has been increased compared to 5 years ago.
LMAT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 22.40 indicates that LMAT is not in any danger for bankruptcy at the moment.
LMAT has a better Altman-Z score (22.40) than 94.79% of its industry peers.
There is no outstanding debt for LMAT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 22.4 |
ROIC/WACC0.89
WACC9.97%
2.3 Liquidity
LMAT has a Current Ratio of 6.51. This indicates that LMAT is financially healthy and has no problem in meeting its short term obligations.
LMAT has a better Current ratio (6.51) than 81.25% of its industry peers.
LMAT has a Quick Ratio of 4.57. This indicates that LMAT is financially healthy and has no problem in meeting its short term obligations.
LMAT has a Quick ratio of 4.57. This is in the better half of the industry: LMAT outperforms 73.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.51 | ||
| Quick Ratio | 4.57 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 44.09% over the past year.
The Earnings Per Share has been growing by 8.05% on average over the past years. This is quite good.
LMAT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.70%.
Measured over the past years, LMAT shows a quite strong growth in Revenue. The Revenue has been growing by 12.87% on average per year.
EPS 1Y (TTM)44.09%
EPS 3Y7.46%
EPS 5Y8.05%
EPS growth Q2Q52%
Revenue 1Y (TTM)19.7%
Revenue growth 3Y14.35%
Revenue growth 5Y12.87%
Revenue growth Q2Q19.37%
3.2 Future
LMAT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.10% yearly.
The Revenue is expected to grow by 7.86% on average over the next years.
EPS Next Y25.79%
EPS Next 2Y18.5%
EPS Next 3Y15.1%
EPS Next 5YN/A
Revenue Next Year9.34%
Revenue Next 2Y8.3%
Revenue Next 3Y7.86%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 55.39, LMAT can be considered very expensive at the moment.
Based on the Price/Earnings ratio, LMAT is valued a bit cheaper than 71.35% of the companies in the same industry.
LMAT is valuated expensively when we compare the Price/Earnings ratio to 28.28, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 44.03 indicates a quite expensive valuation of LMAT.
Based on the Price/Forward Earnings ratio, LMAT is valued a bit cheaper than 73.44% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of LMAT to the average of the S&P500 Index (20.88), we can say LMAT is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 55.39 | ||
| Fwd PE | 44.03 |
4.2 Price Multiples
LMAT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. LMAT is cheaper than 72.40% of the companies in the same industry.
78.65% of the companies in the same industry are more expensive than LMAT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 56.51 | ||
| EV/EBITDA | 31.69 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates LMAT does not grow enough to justify the current Price/Earnings ratio.
LMAT has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as LMAT's earnings are expected to grow with 15.10% in the coming years.
PEG (NY)2.15
PEG (5Y)6.88
EPS Next 2Y18.5%
EPS Next 3Y15.1%
5. Dividend
5.1 Amount
LMAT has a yearly dividend return of 0.96%, which is pretty low.
Compared to an average industry Dividend Yield of 1.68, LMAT pays a better dividend. On top of this LMAT pays more dividend than 93.23% of the companies listed in the same industry.
With a Dividend Yield of 0.96, LMAT pays less dividend than the S&P500 average, which is at 2.41.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.96% |
5.2 History
The dividend of LMAT is nicely growing with an annual growth rate of 14.87%!
LMAT has paid a dividend for at least 10 years, which is a reliable track record.
LMAT has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)14.87%
Div Incr Years12
Div Non Decr Years12
5.3 Sustainability
41.35% of the earnings are spent on dividend by LMAT. This is a bit on the high side, but may be sustainable.
The dividend of LMAT is growing around the same rate as the earnings are growing. If this keeps up the dividend growth is sustainable.
DP41.35%
EPS Next 2Y18.5%
EPS Next 3Y15.1%
LEMAITRE VASCULAR INC
NASDAQ:LMAT (5/3/2024, 7:03:45 PM)
After market: 72.75 -1.47 (-1.98%)74.22
+7.45 (+11.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.67B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.96% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 55.39 | ||
| Fwd PE | 44.03 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)2.15
PEG (5Y)6.88
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.68% | ||
| ROE | 10.11% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 19.22% | ||
| PM (TTM) | 15.56% | ||
| GM | 65.66% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.51 | ||
| Quick Ratio | 4.57 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)44.09%
EPS 3Y7.46%
EPS 5Y
EPS growth Q2Q
EPS Next Y25.79%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)19.7%
Revenue growth 3Y14.35%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y